Animal

PETVIVO HOLDINGS, INC. TO EXHIBIT AT THE IVAPM PAIN MANAGEMENT FORUM IN INDIANAPOLIS, INDIANA

Retrieved on: 
Monday, April 8, 2024
Arthralgia, Osteoarthritis, DVM, Mayra Andrade, Hip, Patient, Synovial joint, Pain management, ACVS, Limp, Quality of life, Trial of the century, Dog, JW Marriott Hotels, JW Marriott Indianapolis, Joint, Pain, CCRT, VOS, Animal, CCD, Poultry farming

PetVivo intends to exhibit its lead product, SPRYNG™ with OsteoCushion™ Technology.

Key Points: 
  • PetVivo intends to exhibit its lead product, SPRYNG™ with OsteoCushion™ Technology.
  • Spryng is an intra-articular injectable veterinary medical device composed of sterilized, extra-cellular matrix microparticles.
  • Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.
  • For more information about PetVivo Holdings, Inc. please contact [email protected] or visit https://petvivo.com/
    Pain Management Forum Exhibit Details:
    Location: The JW Marriott in Indianapolis, Indiana
    Presentation Title: How do we Elevate Our Strategy for Managing Osteoarthritis in Pets?

NatureServe Expands Access to Critical Biodiversity Data with the Launch of NatureServe Explorer Pro

Retrieved on: 
Friday, April 5, 2024
CIO, Science, Exploration, Research, Classification, Biodiversity, NatureServe, Interim, Animal

The advanced platform provides users with unparalleled access to detailed information on at-risk species, reinforcing NatureServe's commitment to conserving biodiversity as the go-to source for decision-quality biodiversity data.

Key Points: 
  • The advanced platform provides users with unparalleled access to detailed information on at-risk species, reinforcing NatureServe's commitment to conserving biodiversity as the go-to source for decision-quality biodiversity data.
  • NatureServe Explorer Pro offers users high-quality biodiversity information for data-driven conservation planning and environmental screening.
  • “NatureServe Explorer Pro is a critical open data platform for discovery, exploration, and dissemination of biodiversity data,” said Patrick Henry, Executive Director of NatureServe Canada.
  • “With powerful mapping tools and detailed data, NatureServe Explorer Pro expands our capacity to deliver high-quality scientific information,” said Lori Scott, Interim CEO and CIO of NatureServe.

FuelPositive Welcomes Deputy Minister of Agriculture and Agri-Food Canada to Facility in Waterloo and Announces Non-Brokered Private Placement

Retrieved on: 
Thursday, April 4, 2024
Sustainability, Climate change, Government, Farmer, TSX Venture Exchange, Debt, Offering, University, Biophysical environment, GHG, Chairperson, Research, Mental health, Policy, Anxiety, Ontario Agricultural College, Rural development, Quality of life, Central Statistics Office (India), EEStor, RPP, Fertilizer, Suicide, MCIP, Animal, Federal, School, Agriculture

"Deputy Minister Beck recently visited our team at our new facility during her visit to the Kitchener-Waterloo region.

Key Points: 
  • "Deputy Minister Beck recently visited our team at our new facility during her visit to the Kitchener-Waterloo region.
  • Deputy Minister Beck was joined by Alec Nicholls, Director General, Agriculture and Agri-Food Canada, Melissa Reginato, Senior Markets and Trade, Agriculture and Agri-Food Canada and Hadley Carpenter, Regional Director, Agriculture and Agri-Food Canada, who was instrumental in organizing the visit.
  • Our technology embodies the spirit of progress and collaboration and showcases Canada's leadership in pioneering solutions that address pressing global challenges.
  • The governmental visit was a valuable opportunity for the FuelPositive team to engage in meaningful discussions with Deputy Minister Beck.

NatureServe Expands Access to Critical Biodiversity Data with the Launch of NatureServe Explorer Pro

Retrieved on: 
Thursday, April 4, 2024
CIO, Science, Exploration, Research, Classification, Biodiversity, NatureServe, Interim, Animal

The advanced platform provides users with unparalleled access to detailed information on at-risk species, reinforcing NatureServe's commitment to conserving biodiversity as the go-to source for decision-quality biodiversity data.

Key Points: 
  • The advanced platform provides users with unparalleled access to detailed information on at-risk species, reinforcing NatureServe's commitment to conserving biodiversity as the go-to source for decision-quality biodiversity data.
  • NatureServe Explorer Pro offers users high-quality biodiversity information for data-driven conservation planning and environmental screening.
  • “NatureServe Explorer Pro is a critical open data platform for discovery, exploration, and dissemination of biodiversity data,” said Patrick Henry, Executive Director of NatureServe Canada.
  • “With powerful mapping tools and detailed data, NatureServe Explorer Pro expands our capacity to deliver high-quality scientific information,” said Lori Scott, Interim CEO and CIO of NatureServe.

PETVIVO HOLDINGS, INC. TO EXHIBIT AT THE ACVSMR SYMPOSIUM IN NAPLES FLORIDA

Retrieved on: 
Wednesday, April 3, 2024
Arthralgia, Osteoarthritis, American College, Joint, Pet, Animal, Sports medicine

PetVivo intends to exhibit its lead product, SPRYNG™ with OsteoCushion™ Technology.

Key Points: 
  • PetVivo intends to exhibit its lead product, SPRYNG™ with OsteoCushion™ Technology.
  • Spryng is an intra-articular injectable veterinary medical device composed of sterilized, extra-cellular matrix microparticles.
  • The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal’s subsynovial tissue.
  • Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.

PETVIVO HOLDINGS, INC. TO EXHIBIT AT THE ACVSMR SYMPOSIUM IN CHARLESTON, SOUTH CAROLINA

Retrieved on: 
Wednesday, April 3, 2024
Arthralgia, Osteoarthritis, American College, Joint, Pet, Animal, Sports medicine

PetVivo intends to exhibit its lead product, SPRYNG™ with OsteoCushion™ Technology.

Key Points: 
  • PetVivo intends to exhibit its lead product, SPRYNG™ with OsteoCushion™ Technology.
  • Spryng is an intra-articular injectable veterinary medical device composed of sterilized, extra-cellular matrix microparticles.
  • The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal’s subsynovial tissue.
  • Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.

Beverly Hills Teddy Bear Company Commemorates 30 Years of Unmatched Creativity and Quality

Retrieved on: 
Tuesday, April 2, 2024
Target, Growth, Socha, Philosophy, Child, Life, Warner Bros., Walmart, The Walt Disney Company, Imagination, Fox, Intellectual property, Family, Babe, Animal, Parent, Toy

Santa Clarita, California, April 02, 2024 (GLOBE NEWSWIRE) -- Beverly Hills Teddy Bear Company (BHTB), a full spectrum toy manufacturer, proudly celebrates its 30th anniversary.

Key Points: 
  • Santa Clarita, California, April 02, 2024 (GLOBE NEWSWIRE) -- Beverly Hills Teddy Bear Company (BHTB), a full spectrum toy manufacturer, proudly celebrates its 30th anniversary.
  • We collaborate with leading companies and studios to turn their imagination into reality," Founder and CEO David Socha remarks.
  • In 1994, Beverly Hills Teddy Bear Company came to life.
  • Now that it commemorates 30 years of spreading joy and creating a world of fun, Beverly Hills Teddy Bear Company plans to diversify its offerings across four pillars: custom plush, evergreen product lines, trend-driven innovations, and charitable initiatives.

Pressure BioSciences’ Uncle Bud’s Subsidiary Reports Significant Demand for New UltraShear CBD Body Revive Spray – First Product in New “Premium Collection”

Retrieved on: 
Tuesday, April 2, 2024
Absorption, Açaí palm, Hemp, D3, UST, Business development, CBD, Human, Collection, Marketing, Plant, Commonwealth, Wellness, OTCQB, Animal, Agriculture, Pharmaceutical industry

CANTON, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBIO” or the “Company”), a leading innovator in high-pressure nanotechnology and a pioneer in the development of novel, broadly-enabling, pressure-based instruments and nanoemulsion products and services for the health & wellness, food & beverage, nutraceutical, cosmeceutical, and other industries, today announced that its wholly-owned Uncle Bud’s Health & Wellness consumer packaged goods subsidiary (“Uncle Bud’s”) has experienced significant sales activity in its revolutionary nanoemulsified CBD product offered in the initial launch of its highly touted “Premium Collection” of UltraShear™ processed nanoemulsion products. Click here for more info on Uncle Bud's Premium Collection.

Key Points: 
  • Click here for more info on Uncle Bud's Premium Collection.
  • The Premium Collection was an immediate success, highlighted by the unprecedented response to its initial product in the Collection - the CBD Body Revive Spray with 1200mg of Nano-CBD.
  • “Uncle Bud’s newly launched Nano-CBD Body Revive Spray, an innovative, all plant-based, organic, highly bioavailable flagship product processed using PBIO’s UltraShear platform, captured an impressive 30% conversion of Uncle Bud’s total CBD Revive Spray product revenue in March alone,” commented John Hollister, PBIO’s Director of Sales and Marketing.
  • This achievement enables PBIO to develop, manufacture, market, and sell UST-processed products into the rapidly expanding CBD marketplace.

Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection

Retrieved on: 
Tuesday, April 2, 2024
S. aureus, Risk, Patient, Tissue, Staphylococcus aureus, Infection, CDC, Staphylococcus, Animal, Antigen, Vaccine

In the animal studies, the EVX-B1 antigens significantly reduced disease burden.

Key Points: 
  • In the animal studies, the EVX-B1 antigens significantly reduced disease burden.
  • Birgitte Rønø, Chief Scientific Officer at Evaxion, expresses enthusiasm: “We are very thrilled about the encouraging data and believe that our EVX-B1 vaccine antigens hold the potential for efficacy in human trials – a milestone that previous vaccine attempts have failed to achieve.”
    There is no S. aureus vaccine available for human use.
  • Also, the presence of antibiotic-resistant S. aureus is limiting available treatment options.
  • The Centers for Disease Control and Prevention (CDC) has reported 120,000 bloodstream infections associated with S. aureus in the US annually.

Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, April 1, 2024
Research, Glucose, Health, Congress, Obesity, Human, Drug discovery, Exercise, Glycated hemoglobin, DMR, ADAS, Partnership, Insulin, IDA, Patient, Weight loss, Michigan Medicine, Diabetes, Public expenditure, IDE, University, IPO, Tropism, Peptide, Transgene, Insulin resistance, Animal, NUB, Type 2 diabetes, Pancreas, Investigational New Drug, Therapy, Food, Marketing, FDA, Engineering, Annual general meeting, Pharmaceutical industry

BURLINGTON, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Fractyl Health (Nasdaq: GUTS), a metabolic therapeutics company focused on pioneering new approaches for the treatment of type 2 diabetes (T2D) and obesity, today reported its fourth quarter and full year 2023 financial results and provided a business update.

Key Points: 
  • “In addition, we expect to complete enrollment of our pivotal Revitalize-1 study and are excited to report topline data in the fourth quarter of 2024.
  • The Company expects to complete enrollment in the first half of 2024 and report topline data in the fourth quarter of 2024.
  • In December 2023, Fractyl presented preclinical findings in an oral presentation at the World Congress of Insulin Resistance Diabetes and Cardiovascular Disease 2023 Annual Meeting.
  • Cash Position: As of December 31, 2023, Fractyl had approximately $33.2 million in cash and cash equivalents.